WEBULL
News
OTLK
0.4209
+4.03%
0.0163
Outlook Therapeutics sumbits Type A meeting request to FDA
TipRanks · 1h ago
Outlook Therapeutics Submits Type A Meeting Request To FDA Following Receipt Of Complete Response Letter Regarding BLA For ONS-5010/LYTENAVA For Wet AMD Treatment
Benzinga · 1h ago
OUTLOOK THERAPEUTICS INC: INTENDS TO CONTINUE TO WORK WITH FDA ON A PATH FORWARD FOR RESOLVING FDA'S REQUEST FOR ADDITIONAL CONFIRMATORY EVIDENCE
Reuters · 1h ago
OUTLOOK THERAPEUTICS SUBMITS TYPE A MEETING REQUEST TO FDA FOLLOWING COMPLETE RESPONSE LETTER
Reuters · 1h ago
Weekly Report: what happened at OTLK last week (0202-0206)?
Weekly Report · 2d ago
Weekly Report: what happened at OTLK last week (0126-0130)?
Weekly Report · 02/02 09:54
Outlook Therapeutics Inc. Announces Date for Upcoming Annual Stockholders Meeting
Reuters · 01/26 22:02
Weekly Report: what happened at OTLK last week (0119-0123)?
Weekly Report · 01/26 09:54
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), Outlook Therapeutics (OTLK) and Johnson & Johnson (JNJ)
TipRanks · 01/22 08:30
Weekly Report: what happened at OTLK last week (0112-0116)?
Weekly Report · 01/19 09:58
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 01/16 21:05
Weekly Report: what happened at OTLK last week (0105-0109)?
Weekly Report · 01/12 09:57
OTLK Stock Crashes 67% in a Week: Here's What You Need to Know
NASDAQ · 01/07 14:53
Largest borrow rate increases among liquid names
TipRanks · 01/07 13:45
Outlook Therapeutics appoints Laura Cantrell as VP, corporate strategy
TipRanks · 01/06 13:50
Largest borrow rate increases among liquid names
TipRanks · 01/06 13:45
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
Reuters · 01/06 13:35
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 01/05 17:05
Outlook Therapeutics Is Maintained at Neutral by Chardan Capital
Dow Jones · 01/05 13:32
Outlook Therapeutics Price Target Cut to $1.00/Share From $3.00 by Chardan Capital
Dow Jones · 01/05 13:32
More
Webull provides a variety of real-time OTLK stock news. You can receive the latest news about Outlook Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About OTLK
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.